<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940352</url>
  </required_header>
  <id_info>
    <org_study_id>CHDM201H12101C</org_study_id>
    <secondary_id>2018-004001-62</secondary_id>
    <nct_id>NCT03940352</nct_id>
  </id_info>
  <brief_title>HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or
      venetoclax in subjects with AML or high-risk MDS.

      For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in
      exons 5, 6, 7 and 8.

      Two treatment arms will enroll subjects in parallel to characterize the safety, tolerability,
      PK, PD and preliminary antitumor activity of HDM201+MBG453 (treatment arm 1) and
      HDM201+venetoclax (treatment arm 2).

        -  In the treatment arm 1, subjects will receive HDM201 in combination with MBG453.

        -  In the treatment arm 2, subjects will receive HDM201 in combination with venetoclax.
           Venetoclax dose will be gradually increased (ramp-up) over a period of 4 to 5 days to
           achieve the daily target dose tested that will be subsequently continued.

      Upon the completion of the escalation part, MTD(s) and/or RD(s) of HDM201 in combination with
      MBG453 or venetoclax in AML and high-risk MDS subjects will be determined for each treatment
      arm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">April 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) of treatment</measure>
    <time_frame>at day 28</time_frame>
    <description>end of first cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interuptions</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>at month 24</time_frame>
    <description>measured in mg/ day Month 24 is assumed to be study end</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS) for AML (Cheson 2003) or Progression Free Survival (PFS) for MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (RFS) for AML (Cheson 2003) or Time To Response (TTR) for MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) for AML (Cheson 2003) and MDS (Cheson 2006)</measure>
    <time_frame>at month 24</time_frame>
    <description>Month 24 is assumed to be study end</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-MBG453 antibodies (treatment arm 1 HD201+MBG453)</measure>
    <time_frame>at Day 1, Day 29 and at month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1, Day 2, Day 5, Day 6 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at Day 1, Day 2, Day 8, Day 11, Day 15, Day 29 and at month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1, Day 2, Day 3, Day 5, Day 6, Day 8, Day 9, Day 14, Day 15 and Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of HDM201 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of MBG453 (treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (AUC) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Cmax) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Tmax) of venetoclax (treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in GDF-15 (Treatment arm 1 HDM201+MBG453 and treatment arm 2 HDM201+venetoclax)</measure>
    <time_frame>at Day 1 and Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in soluble TIM-3 (Treatment arm 1 HDM201+MBG453)</measure>
    <time_frame>at month 6</time_frame>
    <description>Cycle 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>High-risk Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib (escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib (escalation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <description>Capsule</description>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>LIVI (Liquid in vial) Concentrate for Solution for infusion</description>
    <arm_group_label>treatment arm1: HDM201+MBG453</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Tablet</description>
    <arm_group_label>treatment arm2: HDM201+venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female patients ≥ 18 years of age at the date of ICF signature who present
             with one of the following:

               1. Relapsed/refractory AML following ≥1 prior therapies (but ≤3 prior therapies) who
                  have relapsed or exhibited refractory disease (primary failure) and are deemed by
                  the Investigator not to be candidates for standard therapy, including
                  re-induction with cytarabine or other established chemotherapy regimens for
                  patients with AML (patients who are suitable for standard re-induction
                  chemotherapy or hematopoietic stem cell transplantation and willing to receive it
                  are excluded)

               2. First line AML patient unfit for standard induction chemotherapy (includes both
                  de novo and secondary AML), except in countries where approved therapies are
                  available. Patients who are suitable for hematopoietic stem cell transplantation
                  and willing to receive it are excluded.

               3. High-risk MDS patient (high and very high-risk groups according to rIPSS) who
                  have failed hypomethylating agent therapy.

          -  ECOG performance status ≤ 1

          -  TP53wt tumor. At minimum exons 5, 6, 7 and 8 in the TP53 gene must be sequenced and
             determined to contain no mutations. The TP53 status must be obtained from a
             bone-marrow sample, collected no longer than 3 months before signing the main ICF.

          -  Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to
             the institutional guidelines and be willing to undergo a bone marrow aspirate and/or
             biopsy at screening, during and at the end of therapy on this study. Exceptions may be
             considered after documented discussion with Novartis.

        Main Exclusion Criteria:

        Patients eligible for this study must not meet any of the following criteria:

          -  Prior combination treatment with compounds having the same mode of action:

               -  mdm2 or mdm4 inhibitors combined with TIM-3 inhibitors (for patients enrolled in
                  treatment arm1)

               -  mdm2 or mdm4 inhibitors combined with Bcl-2 inhibitor (for patients enrolled in
                  treatment arm2)

          -  History of severe hypersensitivity reactions to any ingredient of study drug(s) and
             other monoclonal antibodies (mAbs) and/or their excipients.

          -  Patients with acute promyelocytic leukemia with PML-RARA.

          -  Allogeneic stem cell transplant (HSCT) within last 6 months and/or active GvHD
             requiring systemic immunosuppressive therapy.

          -  GI disorders impacting absorption of oral HDM201 or venetoclax.

          -  Evidence of active bleeding or bleeding diathesis or major coagulopathy (including
             familial).

          -  Patients with active, known or suspected autoimmune disease (treatment arm 1 only).

        Other eligibility criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN 00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib</keyword>
  <keyword>BHLRM</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <keyword>HDM201</keyword>
  <keyword>TP53</keyword>
  <keyword>MBG453</keyword>
  <keyword>TIM-3</keyword>
  <keyword>venetoclax</keyword>
  <keyword>Bcl-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

